Hemostatic Disorders
Welcome,         Profile    Billing    Logout  
 199 Companies   329 Products   329 Products   164 Mechanisms of Action   13 Trials   3299 News 


«12345678910111213...6768»
  • ||||||||||  Trial completion, Trial completion date:  Velcade (Bortezomib) Consolidation After Transplant (clinicaltrials.gov) -  Mar 8, 2018   
    P3,  N=256, Completed, 
    Active, not recruiting --> Completed | N=50 --> 10 Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Jan 2018
  • ||||||||||  Neupogen (filgrastim) / Kyowa Kirin, Amgen, Mozobil (plerixafor) / Sanofi
    Trial completion, Trial completion date:  Collection of Transplant Stem Cells for Plasma Cell Myeloma (clinicaltrials.gov) -  Mar 7, 2018   
    P2,  N=49, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Jan 2018 Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Jan 2018
  • ||||||||||  Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation (clinicaltrials.gov) -  Mar 7, 2018   
    P=N/A,  N=43, Terminated, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Jan 2018 N=300 --> 43 | Trial completion date: Dec 2019 --> Feb 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2019 --> Feb 2018; FDA released requirement to complete study
  • ||||||||||  Clinical data, Trial completion date, HEOR:  HAMLET: 2-cohort Study of Adult Patients With Severe Hemophilia A in Greece (clinicaltrials.gov) -  Mar 7, 2018   
    P=N/A,  N=72, Active, not recruiting, 
    N=300 --> 43 | Trial completion date: Dec 2019 --> Feb 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2019 --> Feb 2018; FDA released requirement to complete study Trial completion date: Jan 2018 --> Mar 2018
  • ||||||||||  gandotinib (LY 2784544) / Eli Lilly
    Trial completion date:  A Study in Myeloproliferative Disorders (clinicaltrials.gov) -  Mar 6, 2018   
    P1,  N=80, Active, not recruiting, 
    Trial completion date: Jan 2018 --> Mar 2018 Trial completion date: Aug 2018 --> Dec 2019
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date:  FEISTY: Fibrinogen Early In Severe Trauma studY (clinicaltrials.gov) -  Mar 5, 2018   
    P2,  N=100, Completed, 
    Trial completion date: Aug 2018 --> Dec 2019 Recruiting --> Completed | Trial completion date: Jun 2018 --> Feb 2018 | Trial primary completion date: Dec 2017 --> Jan 2018
  • ||||||||||  Trial completion date:  Control of Major Bleeding After Trauma Study (clinicaltrials.gov) -  Mar 3, 2018   
    P2,  N=144, Terminated, 
    Trial completion date: Feb 2018 --> Mar 2018 Trial completion date: Apr 2018 --> Apr 2017
  • ||||||||||  Trial completion, Trial primary completion date:  Comprehensive Frailty Assessment (clinicaltrials.gov) -  Feb 28, 2018   
    P=N/A,  N=111, Completed, 
    Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Aug 2017
  • ||||||||||  CB-5083 / Cleave Therap
    Trial initiation date, Trial primary completion date:  A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies (clinicaltrials.gov) -  Feb 27, 2018   
    P1,  N=120, Terminated, 
    Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Aug 2017 Trial primary completion date: Dec 2018 --> Jul 2017 | Initiation date: Jul 2014 --> Aug 2014
  • ||||||||||  Farydak (panobinostat) / Secura Bio
    Enrollment change, Trial completion date, Trial initiation date, Trial termination, Trial primary completion date:  PANORAMA4: A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM) (clinicaltrials.gov) -  Feb 23, 2018   
    P2,  N=6, Terminated, 
    Trial primary completion date: Dec 2018 --> Jul 2017 | Initiation date: Jul 2014 --> Aug 2014 N=112 --> 6 | Recruiting --> Terminated | Trial primary completion date: Feb 2021 --> May 2017 | Trial completion date: Feb 2021 --> May 2017 | Initiation date: Jun 2016 --> Jun 2016; A study was terminated due to low enrollment.
  • ||||||||||  Epogen (epoetin alfa) / Amgen
    Trial completion, Enrollment change, Trial initiation date, HEOR:  Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma (clinicaltrials.gov) -  Feb 23, 2018   
    P=N/A,  N=31, Completed, 
    N=112 --> 6 | Recruiting --> Terminated | Trial primary completion date: Feb 2021 --> May 2017 | Trial completion date: Feb 2021 --> May 2017 | Initiation date: Jun 2016 --> Jun 2016; A study was terminated due to low enrollment. Active, not recruiting --> Completed | N=50 --> 31 | Initiation date: Mar 2005 --> Sep 2003
  • ||||||||||  Biostate (factor VIII/von Willebrand factor) / CSL Behring
    Trial completion:  Study of Voncento® in Subjects With Von Willebrand Disease (clinicaltrials.gov) -  Feb 22, 2018   
    P4,  N=26, Completed, 
    Active, not recruiting --> Completed | N=50 --> 31 | Initiation date: Mar 2005 --> Sep 2003 Recruiting --> Completed
  • ||||||||||  dexamethasone / Generic mfg., lenalidomide / Generic mfg.
    Trial completion date, Trial primary completion date:  Lenalidomide (Revlimid (clinicaltrials.gov) -  Feb 19, 2018   
    P2,  N=67, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Nov 2017 --> Nov 2017 | Trial primary completion date: Nov 2017 --> Nov 2017 Trial primary completion date: Dec 2017 --> Dec 2018 | Trial completion date: Dec 2017 --> Dec 2018
  • ||||||||||  Kymriah (tisagenlecleucel-T) / Novartis
    Trial completion, Trial completion date:  CART-19 for Multiple Myeloma (clinicaltrials.gov) -  Feb 13, 2018   
    P1,  N=13, Completed, 
    Trial primary completion date: Dec 2018 --> Feb 2018 | Trial completion date: Dec 2018 --> Feb 2018 Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Jan 2018
  • ||||||||||  bortezomib / Generic mfg., bendamustine / Generic mfg.
    Trial termination:  Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma (clinicaltrials.gov) -  Feb 7, 2018   
    P2,  N=24, Terminated, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Jan 2018 Completed --> Terminated; PI left the institution before all data analysis was completed
  • ||||||||||  lenalidomide / Generic mfg.
    Biomarker, Trial termination:  Lenalidomide Maintenance Therapy for Multiple Myeloma (clinicaltrials.gov) -  Feb 6, 2018   
    P2,  N=11, Terminated, 
    Trial primary completion date: Dec 2017 --> Dec 2018 | Initiation date: Feb 2016 --> Feb 2016 Completed --> Terminated; Original investigator left the NIH and the primary outcome was not reached
  • ||||||||||  Kogenate FS (octocog alfa sucrose formulation) / CSL Behring, Bayer
    Enrollment closed, Enrollment change, Trial primary completion date, Patient reported outcomes:  ECHO: Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment (clinicaltrials.gov) -  Feb 5, 2018   
    P=N/A,  N=1482, Active, not recruiting, 
    Trial primary completion date: Sep 2018 --> Dec 2017 Recruiting --> Active, not recruiting | N=2000 --> 1482 | Trial primary completion date: Dec 2020 --> Jan 2018
  • ||||||||||  Jivi (damoctocog alfa pegol) / Bayer
    Trial completion:  Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A (clinicaltrials.gov) -  Feb 1, 2018   
    P=N/A,  N=30, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Dec 2017 Active, not recruiting --> Completed
  • ||||||||||  Istodax (romidepsin) / Astellas, BMS
    Trial termination:  Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma (clinicaltrials.gov) -  Jan 31, 2018   
    P1/2,  N=4, Terminated, 
    Active, not recruiting --> Completed Completed --> Terminated; this study was terminated due to losing financial support, and enrollment challenges
  • ||||||||||  Trial primary completion date:  Individualizing Hemophilia Prophylaxis Using Thromboelastography (clinicaltrials.gov) -  Jan 11, 2018   
    P=N/A,  N=60, Recruiting, 
    Active, not recruiting --> Completed | N=20 --> 11 | Trial primary completion date: Oct 2017 --> Jan 2018 Trial primary completion date: Dec 2017 --> Dec 2018
  • ||||||||||  Phase classification, Trial termination, Trial primary completion date:  Honey in Chronic Immune Thrombocytopenia (clinicaltrials.gov) -  Jan 9, 2018   
    P=N/A,  N=30, Terminated, 
    Trial primary completion date: Dec 2017 --> Dec 2018 Phase classification: P2 --> P=N/A | Suspended --> Terminated | Trial primary completion date: Jan 2017 --> Dec 2017; problem with the candidate (investigator)